BriaPro reports Q1 net loss of $82K; cash at $1; going concern uncertainty

BriaCell Therapeutics Corp.

Net loss $82,123 for three months to Oct 2024 vs $128,026 loss in prior year period.
Total assets $195,979; intangible assets (patents) net $195,978.
Current liabilities $522,835; shareholders' deficit $487,817; cash unchanged at $1.
Due to BriaCell (related party) $503,709; no revenue or commercial operations.
Going concern doubt due to pre-clinical stage and need for additional financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.